RU2020133811A - Фармацевтические комбинации - Google Patents

Фармацевтические комбинации Download PDF

Info

Publication number
RU2020133811A
RU2020133811A RU2020133811A RU2020133811A RU2020133811A RU 2020133811 A RU2020133811 A RU 2020133811A RU 2020133811 A RU2020133811 A RU 2020133811A RU 2020133811 A RU2020133811 A RU 2020133811A RU 2020133811 A RU2020133811 A RU 2020133811A
Authority
RU
Russia
Prior art keywords
amino acid
acid sequence
seq
chain variable
variable domain
Prior art date
Application number
RU2020133811A
Other languages
English (en)
Russian (ru)
Other versions
RU2020133811A3 (cg-RX-API-DMAC7.html
Inventor
Стефан ФЕРРЕТТИ
Нельсон ГЕРРЕЙРО
Энсар ХЕЛАЙЛОВИК
Себастьен ЖЕЭ
Астрид ДЖУЛЛИОН
Цзиншэн ЛЯН
Кристоф МАЙЛЛЕ
Хой-Цинь ВАН
Йенс ВЮРТНЕР
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2020133811A publication Critical patent/RU2020133811A/ru
Publication of RU2020133811A3 publication Critical patent/RU2020133811A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
RU2020133811A 2018-03-20 2019-03-18 Фармацевтические комбинации RU2020133811A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862645754P 2018-03-20 2018-03-20
US62/645,754 2018-03-20
PCT/IB2019/052166 WO2019180576A1 (en) 2018-03-20 2019-03-18 Pharmaceutical combinations

Publications (2)

Publication Number Publication Date
RU2020133811A true RU2020133811A (ru) 2022-04-20
RU2020133811A3 RU2020133811A3 (cg-RX-API-DMAC7.html) 2022-04-20

Family

ID=66251830

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2020133811A RU2020133811A (ru) 2018-03-20 2019-03-18 Фармацевтические комбинации

Country Status (14)

Country Link
US (1) US20210363254A1 (cg-RX-API-DMAC7.html)
EP (1) EP3768717A1 (cg-RX-API-DMAC7.html)
JP (2) JP2021518348A (cg-RX-API-DMAC7.html)
KR (1) KR20200134253A (cg-RX-API-DMAC7.html)
CN (1) CN111868088A (cg-RX-API-DMAC7.html)
AU (2) AU2019240200B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020018755A2 (cg-RX-API-DMAC7.html)
CA (1) CA3092307A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020002379A1 (cg-RX-API-DMAC7.html)
IL (1) IL277334A (cg-RX-API-DMAC7.html)
MX (1) MX2020009614A (cg-RX-API-DMAC7.html)
RU (1) RU2020133811A (cg-RX-API-DMAC7.html)
TW (1) TWI791794B (cg-RX-API-DMAC7.html)
WO (1) WO2019180576A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
EP3191126B1 (en) 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
UY34591A (es) 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
US20130245089A1 (en) 2012-03-19 2013-09-19 Hoffmann-La Roche Inc. Method for administration
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
EP3233918A1 (en) * 2014-12-19 2017-10-25 Novartis AG Combination therapies
EP3328418A1 (en) * 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
ES2962460T3 (es) * 2015-08-28 2024-03-19 Novartis Ag Inhibidores de mdm2 y combinaciones de estos
GB201517217D0 (en) * 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
CN108495651A (zh) * 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
CN108697794A (zh) * 2015-12-17 2018-10-23 诺华股份有限公司 C-met抑制剂和抗pd-1抗体分子的组合及其用途
MX2019011945A (es) * 2017-04-05 2019-11-28 Boehringer Ingelheim Int Terapia de combinacion contra cancer.

Also Published As

Publication number Publication date
US20210363254A1 (en) 2021-11-25
IL277334A (en) 2020-10-29
KR20200134253A (ko) 2020-12-01
CL2020002379A1 (es) 2021-03-05
WO2019180576A1 (en) 2019-09-26
AU2019240200B2 (en) 2022-07-21
BR112020018755A2 (pt) 2021-01-05
CA3092307A1 (en) 2019-09-26
RU2020133811A3 (cg-RX-API-DMAC7.html) 2022-04-20
AU2019240200A1 (en) 2020-09-10
JP2024012300A (ja) 2024-01-30
TW201945001A (zh) 2019-12-01
EP3768717A1 (en) 2021-01-27
CN111868088A (zh) 2020-10-30
TWI791794B (zh) 2023-02-11
JP2021518348A (ja) 2021-08-02
AU2022209328A1 (en) 2022-10-20
MX2020009614A (es) 2020-10-07

Similar Documents

Publication Publication Date Title
RU2018146886A (ru) Пути терапевтического применения ингибитора c-raf
KR102446673B1 (ko) 암 치료를 위한 약물의 제조에 있어서 항-pd-1 항체 및 vegfr 억제제의 조합의 용도
JP2019517549A5 (cg-RX-API-DMAC7.html)
TW202005985A (zh) 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症的方法
RU2017108173A (ru) Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1
JP2021528423A5 (cg-RX-API-DMAC7.html)
CN111132696B (zh) Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途
CN111065411A (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
JP2020508317A5 (cg-RX-API-DMAC7.html)
IL313952A (en) Combination of anti-PD-1 antibodies and bispecific anti-CD20 / anti-CD3 antibodies for cancer treatment
JP2019503349A5 (cg-RX-API-DMAC7.html)
RU2017107559A (ru) Лечение раковых заболеваний с применением анти-nkg2a средств
RU2010145177A (ru) Лекарственное средство для лечения рака печени
JP2017507954A5 (cg-RX-API-DMAC7.html)
JP2015500822A5 (cg-RX-API-DMAC7.html)
RU2014144254A (ru) Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение
RU2014127298A (ru) Применения иммуноконъюгатов, мишенью которых является cd138
JP2021518348A5 (cg-RX-API-DMAC7.html)
JP2025509567A5 (cg-RX-API-DMAC7.html)
RU2014143213A (ru) Соединения ингибитора тирозинкиназы и их применение
JP2025502061A5 (cg-RX-API-DMAC7.html)
CN112955148B (zh) Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途
JP2023500480A5 (cg-RX-API-DMAC7.html)
JP2023531090A5 (cg-RX-API-DMAC7.html)
RU2019108441A (ru) Режим дозирования